Drug Profile
Iduronate-2-sulfatase gene therapy
Alternative Names: Hunter syndrome gene therapyLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator University of Minnesota
- Class Iduronate sulfatases; Recombinant proteins
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mucopolysaccharidosis II
Most Recent Events
- 31 Dec 2007 Discontinued - Phase-II for Mucopolysaccharidosis II in USA (Infusion)
- 31 Dec 2007 Discontinued - Preclinical for Mucopolysaccharidosis II in Italy (unspecified route)
- 11 Dec 2003 No development reported - Phase-II for Mucopolysaccharidosis type II in USA (Infusion)